IMMX

Immix Biopharma Inc

IMMX.US immixbio.com + Research + Basket
CIK 0001873835
Employees 21
Phone 310 651 8041
Fiscal year end December
IPO Dec 16, 2021
Address 11400 West Olympic Boulevard, Los Angeles, CA, United States, 90064
7.98
-0.15 (-1.78%)
USD · NASDAQ
52-week range
2.85
15.10
Trading at 42% of the 52-week range
Market Cap
673.59M
P/E Ratio
0.00
Forward P/E
0.00
Book Value
3.20
Div. Yield
N/A
% Institutions
68.56%
% Insiders
14.78%

1 Year

+114.5%

3 Year

+141.1%

10 Year

+117.4%
Description

Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia. The company' lead product is NXC-201 for relapsed/refractory AL Amyloidos. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California.

Actions

Add an action for IMMX.US, or sign in to see your action list.

People

▼

Directors & Officers

Name Title Year Born
Dr. Ilya Rachman M.B.A., M.D., Ph.D. Co-Founder, CEO, Chief Scientific Officer & Chairman 1973
Mr. Gabriel Morris B.A. President, CFO & Director 1987
Dr. Vladimir P. Torchilin D.Sc., MSE, Ph.D. Scientific Co-Founder 1947
Dr. Graham Ross FFPM, M.D. Chief Medical Officer & Head of Clinical Development 1960
Dr. David Marks MBBS, Ph.D. Chief Medical Officer of Cell Therapy NA
Mr. Mel Davis-Pickett Head of CMC Technical Development NA
Mr. Michael A. Grabow Chief Commercial Officer NA

Insider Trading

Open insider trading
Date Insider Name Title Transaction Type Shares Price Value SEC
Dec 10, 2025 Gabriel S Morris N/A Purchase 770.00 $6.58 $5.07K SEC
Dec 10, 2025 Ilya M Rachman N/A Purchase 746.00 $6.67 $4.98K SEC
Sep 17, 2025 Ilya M Rachman N/A Purchase 2.50K $2.02 $5.05K SEC
Sep 16, 2025 Gabriel S Morris N/A Purchase 2.60K $1.97 $5.12K SEC
Jun 18, 2025 Gabriel S Morris N/A Purchase 2.23K $2.28 $5.07K SEC
Jun 18, 2025 Ilya M Rachman N/A Purchase 2.18K $2.29 $4.99K SEC

Shareholders

▼

Institutional Holders

Holder Name Shares Date Reported % Out Value % Change
The Goldman Sachs Group Inc 174.11K Jun 30, 2026 0.21% $0.00 82.49%

Fund Holdings

Rank Holder Name Shares Held % of Shares Change Date Reported
1 Eventide Healthcare & Life Sciences I 3.89M 4.69% ▲ 52.65% Jun 30, 2026
2 Vanguard MStar Total Stk Mkt Idx Invest 2.24M 2.70% ▲ 25.64% Sep 30, 2026
3 State Street® SPDR® S&P® Biotech ETF 2.07M 2.50% ▼ 1.87% Sep 30, 2026
4 Janus Henderson Hrzn Biotec E2 USD 1.95M 2.35% ▲ 34.14% Jun 30, 2026
5 iShares Russell 2000 ETF 1.54M 1.86% ▼ 1.14% Sep 30, 2026
6 Franklin Biotechnology Discv A(acc)USD 1.14M 1.38% ▲ 86.62% Sep 30, 2026
7 Columbia Small Cap Growth Inst 749.61K 0.90% ▲ 0.00% Aug 31, 2026
8 Franklin Biotechnology Discovery A 645.10K 0.78% ▲ 80.68% Sep 30, 2026
9 iShares Russell 2000 Growth ETF 556.53K 0.67% ▼ 0.13% Sep 30, 2026
10 Columbia Small Cap Value Discv A 486.63K 0.59% ▲ 0.62% Aug 31, 2026

Financial Highlights

▼
Market Cap: $673.59M
EBITDA: $-41.48M
Book Value: $3.20
Earnings/Share: $-0.88
Profit Margin: 0.00%
Operating Margin: 0.00%
ROA (TTM): -20.52%
ROE (TTM): -34.18%
Revenue (TTM): $0.00
Revenue/Share (TTM): $0.00
Earnings Growth (YOY): 0.00%
Revenue Growth (YOY): 0.00%

Valuation Metrics

Enterprise Value: $436.26M
Trailing P/E: 0.00
Forward P/E: 0.00

Shares Statistics

Shares Outstanding: 82.90M
Shares Float: 58.27M
% Insiders: 14.78%
% Institutions: 68.56%
Shares Short: 10.71M
Shares Short (Prior Month): 10.39M
Short Ratio: 6.20
Short % Float: 15.17%

Stock Price History

▼

1 Year Price History

3 Years Price History

10 Years Price History

Max Price History

Financial Charts

▼
Open balance sheet Open capital intensity Download Financials (Excel)

Revenue, Net Income & Operating Cash Flow (Yearly)

Change % vs Prior Year

Revenue, Net Income & Operating Cash Flow (Quarterly)

Change % vs Prior Quarter

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Yearly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Income Statement Waterfall

▼
Open full waterfall Open balance sheet
Line Item
Step Type
Value
Revenue
adjust
$0.00
Cost of Goods Sold
adjust
$-364.50K
Gross Profit
subtotal
$-364.50K
SG&A
adjust
$-13.70M
R&D
adjust
$-16.26M
Operating Income
subtotal
$-29.96M
Other / Non-Operating Items
adjust
$517.80K
Net Income
subtotal
$-29.44M

Earnings Per Share (EPS) History

▼

Financial Ratios

▼

📦 Raw API Data (JSON Explorer)

▼

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about IMMX.US!